Luca Peruzzotti-Jametti
Overview
Explore the profile of Luca Peruzzotti-Jametti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
1411
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Allen-Philbey K, De Trane S, Mao Z, Alvarez-Gonzalez C, Mathews J, MacDougall A, et al.
Ther Adv Neurol Disord
. 2022 Feb;
14:17562864211057661.
PMID: 35173808
Objective: To report on safety and effectiveness of subcutaneous cladribine (Litak) in multiple sclerosis (MS) patients. Methods: Litak was offered to MS-patients irrespective of disease course. Litak 10 mg was...
22.
Jarvis L, Rainbow D, Coppard V, Howlett S, Georgieva Z, Davies J, et al.
Commun Biol
. 2021 Oct;
4(1):1186.
PMID: 34650224
The adoptive transfer of regulatory T-cells (Tregs) is a promising therapeutic approach in transplantation and autoimmunity. However, because large cell numbers are needed to achieve a therapeutic effect, in vitro...
23.
Smith J, Nicaise A, Ionescu R, Hamel R, Peruzzotti-Jametti L, Pluchino S
Front Cell Dev Biol
. 2021 Jul;
9:696434.
PMID: 34307372
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system characterized by demyelination and axonal degeneration. MS patients typically present with a relapsing-remitting (RR) disease course, manifesting...
24.
Peruzzotti-Jametti L, Willis C, Hamel R, Krzak G, Pluchino S
Front Immunol
. 2021 Jul;
12:705920.
PMID: 34249016
Compelling evidence exists that patients with chronic neurological conditions, which includes progressive multiple sclerosis, display pathological changes in neural metabolism and mitochondrial function. However, it is unknown if a similar...
25.
Peruzzotti-Jametti L, Bernstock J, Willis C, Manferrari G, Rogall R, Fernandez-Vizarra E, et al.
PLoS Biol
. 2021 Apr;
19(4):e3001166.
PMID: 33826607
Neural stem cell (NSC) transplantation induces recovery in animal models of central nervous system (CNS) diseases. Although the replacement of lost endogenous cells was originally proposed as the primary healing...
26.
Krzak G, Willis C, Smith J, Pluchino S, Peruzzotti-Jametti L
Trends Immunol
. 2020 Dec;
42(1):45-58.
PMID: 33279412
The rapidly evolving area of immunometabolism has shed new light on the fundamental properties of products and intermediates of cellular metabolism (metabolites), highlighting their key signaling roles in cell-to-cell communication....
27.
Willis C, Nicaise A, Hamel R, Pappa V, Peruzzotti-Jametti L, Pluchino S
Front Cell Neurosci
. 2020 Nov;
14:590960.
PMID: 33250716
Increasing evidence foresees the of neural stem cells (NSCs) to confer superimposable beneficial properties as exogenous NSC transplants in experimental treatments of traumas and diseases of the central nervous system...
28.
Cunniffe N, Vuong K, Ainslie D, Baker D, Beveridge J, Bickley S, et al.
J Neurol Neurosurg Psychiatry
. 2020 Nov;
92(3):295-302.
PMID: 33184094
Objective: To establish a rigorous, expert-led, evidence-based approach to the evaluation of licensed drugs for repurposing and testing in clinical trials of people with progressive multiple sclerosis (MS). Methods: We...
29.
Sullivan G, Knutsen A, Peruzzotti-Jametti L, Korotcov A, Bosomtwi A, Dardzinski B, et al.
Acta Neuropathol Commun
. 2020 Jun;
8(1):84.
PMID: 32517808
Multiple Sclerosis (MS) causes neurologic disability due to inflammation, demyelination, and neurodegeneration. Immunosuppressive treatments can modify the disease course but do not effectively promote remyelination or prevent long term neurodegeneration....
30.
Pluchino S, Smith J, Peruzzotti-Jametti L
Trends Mol Med
. 2020 May;
26(10):898-912.
PMID: 32448751
Multiple disease-modifying medications with regulatory approval to treat multiple sclerosis (MS) are unable to prevent inflammatory tissue damage in the central nervous system (CNS), and none directly promote repair. Thus,...